+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Cognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline Review, H2 2020

  • PDF Icon

    Drug Pipelines

  • 83 Pages
  • July 2020
  • Region: Global
  • Global Markets Direct
  • ID: 5137286
1h Free Analyst Time
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

Cognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline Review, H2 2020

Summary

The publisher's latest Pharmaceutical and Healthcare disease pipeline guide Cognitive Impairment Associated With Schizophrenia - Pipeline Review, H2 2020, provides an overview of the Cognitive Impairment Associated With Schizophrenia (Central Nervous System) pipeline landscape.

Cognitive functioning is moderately to severely impair in patients with schizophrenia. Symptoms include poor executive functioning, inability to sustain attention and problems with working memory. Predisposing factors include family history, age and autoimmune diseases. Treatment includes antipsychotic medications.

Report Highlights

The publisher's Pharmaceutical and Healthcare latest pipeline guide Cognitive Impairment Associated With Schizophrenia - Pipeline Review, H2 2020, provides comprehensive information on the therapeutics under development for Cognitive Impairment Associated With Schizophrenia (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Cognitive Impairment Associated With Schizophrenia (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Cognitive Impairment Associated With Schizophrenia (CIAS) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I and Preclinical stages are 7, 6 and 10 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.

Cognitive Impairment Associated With Schizophrenia (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Cognitive Impairment Associated With Schizophrenia (Central Nervous System).
  • The pipeline guide reviews pipeline therapeutics for Cognitive Impairment Associated With Schizophrenia (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Cognitive Impairment Associated With Schizophrenia (Central Nervous System) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Cognitive Impairment Associated With Schizophrenia (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Cognitive Impairment Associated With Schizophrenia (Central Nervous System)

Reasons to Buy
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Cognitive Impairment Associated With Schizophrenia (Central Nervous System).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Cognitive Impairment Associated With Schizophrenia (Central Nervous System) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

Introduction
  • Report Coverage

Cognitive Impairment Associated With Schizophrenia (CIAS) - Overview
Cognitive Impairment Associated With Schizophrenia (CIAS) - Therapeutics Development
  • Pipeline Overview
  • Pipeline by Companies
  • Pipeline by Universities/Institutes
  • Products under Development by Companies
  • Products under Development by Universities/Institutes

Cognitive Impairment Associated With Schizophrenia (CIAS) - Therapeutics Assessment
  • Assessment by Target
  • Assessment by Mechanism of Action
  • Assessment by Route of Administration
  • Assessment by Molecule Type

Cognitive Impairment Associated With Schizophrenia (CIAS) - Companies Involved in Therapeutics Development
  • Accure Therapeutics SL
  • Anvyl LLC
  • Astellas Pharma Inc
  • AstraZeneca Plc
  • Autifony Therapeutics Ltd
  • Biogen Inc
  • Boehringer Ingelheim International GmbH
  • Bristol-Myers Squibb Co
  • Cadent Therapeutics Inc
  • Coronis NeuroSciences Ltd
  • F. Hoffmann-La Roche Ltd
  • H. Lundbeck AS
  • Neurocrine Biosciences Inc
  • Pfizer Inc
  • SK Biopharmaceuticals Co Ltd
  • Spherium Biomed SL
  • Suven Life Sciences Ltd
  • Vanda Pharmaceuticals Inc

Cognitive Impairment Associated With Schizophrenia (CIAS) - Drug Profiles
ACT-02 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress

ASP-5736 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress

AUT-1 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress

AUT-6 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress

AUT-9 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress

AVL-3288 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress

basmisanil - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress

BI-425809 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress

BIIB-104 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress

BMS-955829 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress

CAD-8688 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress

CAD-9303 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress

CP-102 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress

LuAF-88434 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress

PF-03463275 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress

Cognitive Impairment Associated With Schizophrenia (CIAS) - Dormant ProjectsCognitive Impairment Associated With Schizophrenia (CIAS) - Discontinued Products
Cognitive Impairment Associated With Schizophrenia (CIAS) - Product Development Milestones
  • Featured News & Press Releases
  • Feb 01, 2015: ASCIL Biopharm cooperates in a Project awarded with a “RETOS-Colaboración” grant
  • Jan 27, 2015: Spark, a new public-private project created to develop a drug to fight the cognitive impairment associated with schizophrenia
  • Apr 17, 2013: SK Biopharma Announces FDA's Authorization Of IND For SKL15508 For Treatment Of Cognitive Impairment Associated With Schizophrenia

Appendix
  • Methodology
  • Coverage
  • Secondary Research
  • Primary Research
  • Expert Panel Validation
  • Contact
  • Disclaimer

List of Tables
  • Number of Products under Development for Cognitive Impairment Associated With Schizophrenia (CIAS), H2 2020
  • Number of Products under Development by Companies, H2 2020
  • Number of Products under Development by Universities/Institutes, H2 2020
  • Products under Development by Companies, H2 2020
  • Products under Development by Companies, H2 2020 (Contd..1), H2 2020
  • Products under Development by Universities/Institutes, H2 2020
  • Number of Products by Stage and Target, H2 2020
  • Number of Products by Stage and Mechanism of Action, H2 2020
  • Number of Products by Stage and Route of Administration, H2 2020
  • Number of Products by Stage and Molecule Type, H2 2020
  • Cognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline by Accure Therapeutics SL, H2 2020
  • Cognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline by Anvyl LLC, H2 2020
  • Cognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline by Astellas Pharma Inc, H2 2020
  • Cognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline by AstraZeneca Plc, H2 2020
  • Cognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline by Autifony Therapeutics Ltd, H2 2020
  • Cognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline by Biogen Inc, H2 2020
  • Cognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline by Boehringer Ingelheim International GmbH, H2 2020
  • Cognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline by Bristol-Myers Squibb Co, H2 2020
  • Cognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline by Cadent Therapeutics Inc, H2 2020
  • Cognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline by Coronis NeuroSciences Ltd, H2 2020
  • Cognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline by F. Hoffmann-La Roche Ltd, H2 2020
  • Cognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline by H. Lundbeck AS, H2 2020
  • Cognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline by Neurocrine Biosciences Inc, H2 2020
  • Cognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline by Pfizer Inc, H2 2020
  • Cognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline by SK Biopharmaceuticals Co Ltd, H2 2020
  • Cognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline by Spherium Biomed SL, H2 2020
  • Cognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline by Suven Life Sciences Ltd, H2 2020
  • Cognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline by Vanda Pharmaceuticals Inc, H2 2020
  • Cognitive Impairment Associated With Schizophrenia (CIAS) - Dormant Projects, H2 2020
  • Cognitive Impairment Associated With Schizophrenia (CIAS) - Dormant Projects, H2 2020 (Contd..1), H2 2020
  • Cognitive Impairment Associated With Schizophrenia (CIAS) - Dormant Projects, H2 2020 (Contd..2), H2 2020
  • Cognitive Impairment Associated With Schizophrenia (CIAS) - Discontinued Products, H2 2020

List of Figures
  • Number of Products under Development for Cognitive Impairment Associated With Schizophrenia (CIAS), H2 2020
  • Number of Products under Development by Companies, H2 2020
  • Number of Products by Top 10 Targets, H2 2020
  • Number of Products by Stage and Top 10 Targets, H2 2020
  • Number of Products by Top 10 Mechanism of Actions, H2 2020
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2020
  • Number of Products by Routes of Administration, H2 2020
  • Number of Products by Stage and Routes of Administration, H2 2020
  • Number of Products by Molecule Types, H2 2020
  • Number of Products by Stage and Molecule Types, H2 2020

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

  • Accure Therapeutics SL
  • Anvyl LLC
  • Astellas Pharma Inc
  • AstraZeneca Plc
  • Autifony Therapeutics Ltd
  • Biogen Inc
  • Boehringer Ingelheim International GmbH
  • Bristol-Myers Squibb Co
  • Cadent Therapeutics Inc
  • Coronis NeuroSciences Ltd
  • F. Hoffmann-La Roche Ltd
  • H. Lundbeck AS
  • Neurocrine Biosciences Inc
  • Pfizer Inc
  • SK Biopharmaceuticals Co Ltd
  • Spherium Biomed SL
  • Suven Life Sciences Ltd
  • Vanda Pharmaceuticals Inc